{
  "directed": true,
  "graph": {
    "annotation_list": {
      "Custom_Disease": [
        "COVID-19"
      ],
      "PublicationStatus": [
        "Preprint",
        "Published"
      ],
      "PublicationType": [
        "Commnent",
        "Research",
        "Review"
      ],
      "Section": [
        "Abstract",
        "Full Text",
        "Results"
      ]
    },
    "annotation_pattern": {},
    "annotation_url": {
      "Species": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Shounak Baksi",
      "contact": "shounak.baksi@causalitybiomodels.com",
      "copyright": "Copyright © 2020 Fraunhofer Institute SCAI, All rights reserved",
      "description": "COVID Knowledge Curation project",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "name": "32113509.bel",
      "version": "2.0.0"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns",
      "DRUGBANK": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/drugbank/drugbank-20180906.belns",
      "GO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns",
      "HGNC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns",
      "MESH": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns",
      "TAX": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
    },
    "path": "32113509.bel",
    "pybel_version": "0.14.6"
  },
  "links": [
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms.1,2",
      "key": "a9ae794134e11c2411ac678688df9783",
      "line": 82,
      "relation": "positiveCorrelation",
      "source": 15,
      "target": 17
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "09548b2c6ba6311b781eedfdf61ac888",
      "line": 99,
      "relation": "positiveCorrelation",
      "source": 15,
      "target": 14
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms.1,2",
      "key": "9c99c029c7931f841ab5e53c047c4ad6",
      "line": 82,
      "relation": "positiveCorrelation",
      "source": 17,
      "target": 15
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms.1,2",
      "key": "192bc73a66c7f58a7fa4cf5338222e16",
      "line": 83,
      "relation": "positiveCorrelation",
      "source": 17,
      "target": 16
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms.1,2",
      "key": "9d34e60a949e6a24af6c97f9ead853f3",
      "line": 83,
      "relation": "positiveCorrelation",
      "source": 16,
      "target": 17
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "The drug targets are members of the numb-associated kinase (NAK) family—including AAK1 and GAK—the inhibition of which has been shown to reduce viral infection in vitro.5,6 Baricitinib was identified as a NAK inhibitor, with a particularly high affinity for AAK1, a pivotal regulator of clathrinmediated endocytosis. We suggested that this drug could be of use in countering SARS-CoV-2 infections, subject to appropriate clinical testing.",
      "key": "f1e4fe884d18a366f96ac0423794ca99",
      "line": 87,
      "relation": "decreases",
      "source": 3,
      "target": 13
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "The drug targets are members of the numb-associated kinase (NAK) family—including AAK1 and GAK—the inhibition of which has been shown to reduce viral infection in vitro.5,6 Baricitinib was identified as a NAK inhibitor, with a particularly high affinity for AAK1, a pivotal regulator of clathrinmediated endocytosis. We suggested that this drug could be of use in countering SARS-CoV-2 infections, subject to appropriate clinical testing.",
      "key": "052c5e0afa769107873a3c1eb98affca",
      "line": 89,
      "relation": "decreases",
      "source": 3,
      "target": 6
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "3e5a7a6235a548a53e0c6609d3f73dbb",
      "line": 93,
      "relation": "decreases",
      "source": 3,
      "target": 7
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "e1740cedab7d8c320cf9055229a5b773",
      "line": 98,
      "relation": "decreases",
      "source": 3,
      "target": 14
    },
    {
      "key": "3bc02bd26d27567d8dd4113bcb432bfd",
      "relation": "partOf",
      "source": 3,
      "target": 10
    },
    {
      "key": "f267cebd037ca93de8100ed23993e8db",
      "relation": "partOf",
      "source": 3,
      "target": 11
    },
    {
      "key": "0f44e077e921c08583f3a78cc34cd392",
      "relation": "partOf",
      "source": 3,
      "target": 12
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "The drug targets are members of the numb-associated kinase (NAK) family—including AAK1 and GAK—the inhibition of which has been shown to reduce viral infection in vitro.5,6 Baricitinib was identified as a NAK inhibitor, with a particularly high affinity for AAK1, a pivotal regulator of clathrinmediated endocytosis. We suggested that this drug could be of use in countering SARS-CoV-2 infections, subject to appropriate clinical testing.",
      "key": "91cca30e8495517c33afafada290c448",
      "line": 88,
      "relation": "regulates",
      "source": 13,
      "target": 8
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "da156e3e48610f58f3b19932daa05fc1",
      "line": 94,
      "relation": "decreases",
      "source": 4,
      "target": 7
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "de68df028b23dae3ef9c584daffbb91d",
      "line": 97,
      "relation": "decreases",
      "source": 4,
      "target": 14
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "3f0aa7e4b94956061faa2faf496f718f",
      "line": 95,
      "relation": "decreases",
      "source": 2,
      "target": 7
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "c97b5315aeb25b8d1d715e02617ed9e6",
      "line": 96,
      "relation": "decreases",
      "source": 2,
      "target": 14
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Baricitinib, fedratinib, and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis.All three are powerful antiinflammatories that, as JAK–STAT signalling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines (including interferon-γ) typically observed in people with COVID-19·2",
      "key": "f0c56db2696bf06cf0ba01be4bd19407",
      "line": 99,
      "relation": "positiveCorrelation",
      "source": 14,
      "target": 15
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "b9572d200d1f02757b432fe2a311735f",
      "line": 103,
      "relation": "decreases",
      "source": 0,
      "target": 15
    },
    {
      "key": "6c31415761e1d824940a56e613b1f10c",
      "relation": "partOf",
      "source": 0,
      "target": 10
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "19322ac11d54b7b9ad33acdd16b84c40",
      "line": 104,
      "relation": "decreases",
      "source": 1,
      "target": 15
    },
    {
      "key": "4139a1862396d443df25b3cb24a78af2",
      "relation": "partOf",
      "source": 1,
      "target": 11
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "9527664fc2159fd133412f02c7f50835",
      "line": 105,
      "relation": "decreases",
      "source": 5,
      "target": 15
    },
    {
      "key": "0b9b1a55748029ee7dbdbfc6ff227897",
      "relation": "partOf",
      "source": 5,
      "target": 12
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "27f0d8baa6261ee9bdd754afccd4f583",
      "line": 107,
      "relation": "decreases",
      "source": 10,
      "target": 15
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "7d18b6bff5af0f08178f6f9f17619e9f",
      "line": 110,
      "relation": "decreases",
      "source": 10,
      "target": 18
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "3a8c97e8826e9adbfaf0bbe8032d3d1c",
      "line": 113,
      "relation": "decreases",
      "source": 10,
      "target": 9
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "7601f8f9b594f40bf0bab5c268230c48",
      "line": 116,
      "relation": "decreases",
      "source": 10,
      "target": 17
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "bffe8a0abea5126ab5bab58a032ebff2",
      "line": 108,
      "relation": "decreases",
      "source": 11,
      "target": 15
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "ab05eb500bdbccda5a1bbeae6459545b",
      "line": 111,
      "relation": "decreases",
      "source": 11,
      "target": 18
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "74d798aa70e8edab1648c9fdb5b92ba3",
      "line": 114,
      "relation": "decreases",
      "source": 11,
      "target": 9
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "0c329d8508f32286c2642734ed6ce4dc",
      "line": 117,
      "relation": "decreases",
      "source": 11,
      "target": 17
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "eaf20748a601e1f2f20d24c6cb126533",
      "line": 109,
      "relation": "decreases",
      "source": 12,
      "target": 15
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "0cae3658ce8c4c1df05081c10e18389f",
      "line": 112,
      "relation": "decreases",
      "source": 12,
      "target": 18
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "6b3a7089daf68173b379f5bb495d5180",
      "line": 115,
      "relation": "decreases",
      "source": 12,
      "target": 9
    },
    {
      "annotations": {
        "Custom_Disease": {
          "COVID-19": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Commnent": true
        },
        "Section": {
          "Results": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Griffin I",
          "Oechsle O",
          "Phelan A",
          "Richardson P",
          "Smith D",
          "Stebbing J",
          "Tucker C"
        ],
        "date": "2020-04-01",
        "db": "PubMed",
        "db_id": "32113509",
        "db_name": "The Lancet. Infectious diseases",
        "first": "Stebbing J",
        "last": "Richardson P",
        "pages": "400-402",
        "volume": "20"
      },
      "evidence": "Furthermore, there is the potential for combining baricitinib with the directacting antivirals (lopinavir or ritonavir and 121304016) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drugmetabolising enzymes.Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.",
      "key": "1455d9e86f19535592271b30248f422a",
      "line": 118,
      "relation": "decreases",
      "source": 12,
      "target": 17
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:lopinavir)",
      "concept": {
        "name": "lopinavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "540f0a29f78ff437222f25e1c2e1b0fd"
    },
    {
      "bel": "a(CHEBI:ritonavir)",
      "concept": {
        "name": "ritonavir",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "07c1651afef7019b0cb107f1ce5fef12"
    },
    {
      "bel": "a(CHEBI:ruxolitinib)",
      "concept": {
        "name": "ruxolitinib",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "11825da33b16f8b53f1ea1f623158bca"
    },
    {
      "bel": "a(DRUGBANK:DB11817)",
      "concept": {
        "name": "DB11817",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "2d25a20ec18a05bb4a231bf2e30f3fd8"
    },
    {
      "bel": "a(DRUGBANK:DB12500)",
      "concept": {
        "name": "DB12500",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "71947278fc5fba666569c932369d4c81"
    },
    {
      "bel": "a(PUBCHEM:121304016)",
      "concept": {
        "name": "121304016",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "7704f9ea62204912dace9e0cfb704c95"
    },
    {
      "bel": "a(TAX:\"Severe acute respiratory syndrome coronavirus 2\")",
      "concept": {
        "name": "Severe acute respiratory syndrome coronavirus 2",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "c41851da59cc36c21b2e8acf24c1f46d"
    },
    {
      "bel": "bp(GO:\"JAK-STAT cascade\")",
      "concept": {
        "name": "JAK-STAT cascade",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "67c0e73180af1fa505581ac68e0b88ce"
    },
    {
      "bel": "bp(GO:\"clathrin-dependent endocytosis\")",
      "concept": {
        "name": "clathrin-dependent endocytosis",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "27f8cb71329fa31a19d34b3b9b3c8b67"
    },
    {
      "bel": "bp(GO:\"viral genome replication\")",
      "concept": {
        "name": "viral genome replication",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "e08b08a1af1179857efa22393f4badf4"
    },
    {
      "bel": "composite(a(CHEBI:lopinavir), a(DRUGBANK:DB11817))",
      "function": "Composite",
      "id": "844c7b14acf1b5cd9399222065529c24",
      "members": [
        {
          "bel": "a(CHEBI:lopinavir)",
          "concept": {
            "name": "lopinavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "540f0a29f78ff437222f25e1c2e1b0fd"
        },
        {
          "bel": "a(DRUGBANK:DB11817)",
          "concept": {
            "name": "DB11817",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "2d25a20ec18a05bb4a231bf2e30f3fd8"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:ritonavir), a(DRUGBANK:DB11817))",
      "function": "Composite",
      "id": "9eaf0f1c0495cc9911b73dd11adaee9d",
      "members": [
        {
          "bel": "a(CHEBI:ritonavir)",
          "concept": {
            "name": "ritonavir",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "07c1651afef7019b0cb107f1ce5fef12"
        },
        {
          "bel": "a(DRUGBANK:DB11817)",
          "concept": {
            "name": "DB11817",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "2d25a20ec18a05bb4a231bf2e30f3fd8"
        }
      ]
    },
    {
      "bel": "composite(a(DRUGBANK:DB11817), a(PUBCHEM:121304016))",
      "function": "Composite",
      "id": "41fb36fa2af047131a7c1cb86dd2a239",
      "members": [
        {
          "bel": "a(DRUGBANK:DB11817)",
          "concept": {
            "name": "DB11817",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "2d25a20ec18a05bb4a231bf2e30f3fd8"
        },
        {
          "bel": "a(PUBCHEM:121304016)",
          "concept": {
            "name": "121304016",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "7704f9ea62204912dace9e0cfb704c95"
        }
      ]
    },
    {
      "bel": "p(HGNC:AAK1)",
      "concept": {
        "name": "AAK1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "57a255df8538f93bf3a0a5eedb06635e"
    },
    {
      "bel": "p(HGNC:IFNG)",
      "concept": {
        "name": "IFNG",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "20367a6ea54ae1032be4f48276f3c524"
    },
    {
      "bel": "path(DO:\"COVID-19\")",
      "concept": {
        "name": "COVID-19",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "6f9f1c2e8012537e503a758c6bfaff0f"
    },
    {
      "bel": "path(DO:\"severe acute respiratory syndrome\")",
      "concept": {
        "name": "severe acute respiratory syndrome",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "06fc6690e6ddfff254197e953a470c95"
    },
    {
      "bel": "path(MESH:Inflammation)",
      "concept": {
        "name": "Inflammation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10cd96fd4056a5e6c27264e0130e89f9"
    },
    {
      "bel": "path(MESH:Virulence)",
      "concept": {
        "name": "Virulence",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "cd22afe1d9d585df2f0e1a10fc161447"
    }
  ]
}